Use of a long-acting gonadotropin-releasing hormone agonist for treatment of steroid cell tumors of the ovary

Fertility and Sterility

Volumn 69, Issue 2, 1998, Pages 353-355

  Wang, Peng Hui ^a   Chao, Hsiang Tai ^a,b   Lee, Wen Ling ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Gonadotropin releasing hormone agonist (GnRH a); Not otherwise specified; Steroid cell tumor of the ovary; Testosterone

Indexed keywords

GONADORELIN AGONIST; TESTOSTERONE;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER STAGING; CASE REPORT; DOSE RESPONSE; FEMALE; HORMONAL REGULATION; HUMAN; LEYDIG CELL; NUCLEAR MEDICINE; OVARY TUMOR; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 0031930785     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(97)00500-1     Document Type: Article

References (15)

1. Young RH, Path FRC, Scully RE. Sex cord-stromal, steroid cell, and other ovarian tumors with endocrine, paraendocrine, and paraneoplastic manifestations. In: Kurman RJ, (editor.) Blaustein's pathology of the female genital tract. New York: Springer-Verlag, 1994: 783-847.
2. Kennedy L, Traub A, Atkinson AB. Short term administration of gonadotropin releasing hormone analog to a patient with a testosterone secreting ovarian tumor. J Clin Endo Meta 1987;64:1320-2.
3. Steingold KA, Howard LJ, Neiberg RK, et al. Treatment of severe androgen excess due to ovarian hyperthecosis with long acting gonadotropin-releasing hormone agonist. Am J Obstet Gynecol 1986;154:1241-8.
4. Pascale MM, Pugeat M, Roberts M, et al. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumors. Clin Endocrinol 1994;411:571-6.
5. Schencker Y, Malozowski SN, Ayers J. Steroid secretion by a virilising lipoid cell ovarian tumor: origin of dehydroepiandrosterone sulfate. Obstet Gynecol 1989;74:502-6.
6. Hayes MC, Scully RE. Ovarian steroid cell tumor (not otherwise specified): a clinicopathological analysis of 63 cases. Am J Surg Pathol 1987;11:835-45.
7. Taylor HB, Norris HJ. Lipid cell tumors of the ovary. Cancer 1967;20:1953.
8. Imai A, Lida K, Tamaya T. Direct action of gpnadotropin-releasing hormone (LHRH) analogue on ovary: an alternative acting mechanism of buserelin. Arch Gynecol Obstet 1991;248:117-21.
9. Yoshimura Y, Nakamura Y, Ando M, et al. Direct effect of gonadotropin-releasing hormone agonists on rabbit ovarian follicle. Fertil Steril 1992;57:1091-7.
10. Lamberts SWJ, Timmers JM, Oosterom R, et al. Testosterone secretion by cultured arrhenoblastoma cells: Suppression by luteinizing hormone releasing hormone agonist. J Clin Endocrine Meta 1982;54:450-4.
11. Emons G, Ortmann O, Becker M, et al. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 1993;53:5439-46.
12. Takagi H, Imai A, Furui T, Horibe S, Fuseya T, Tamaya T. Evidence for tight coupling of gonadotropin-releasing hormone receptors to phosphatidylinositol kinase in plasma membrane from ovarian carcinomas. Gynecol Oncol 1995;58:110-5.
13. Palyi I, Vincze B, Kalnay A, et al. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor-positive human cancer cell lines. Cancer Detect Prevent 1996;20:146-52.
14. Vincze B, Palyi I, Gaal D, et al. In vivo studies of the new gonadotropin-releasing hormone antagonist-copolymer conjugates having antitumor activity. Cancer Detect Prevent 1996;20:153-9.
15. Ho MN, Delgado CH, Owens GA, Steller MA. Insulin-like growth factor-II participates in the biphasic effect of a gonadotropin-releasing hormone agonist on ovarian cancer cell growth. Fertil Steril 1997;67:870-6.